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Abstract
Background: Cystic fibrosis (CF) is caused by mutations in the CFTR gene that impair the function of CFTR, a
cAMP-regulated anion channel. In the small intestine loss of CFTR function creates a dehydrated, acidic luminal
environment which is believed to cause an accumulation of mucus, a phenotype characteristic of CF. CF mice have
small intestinal bacterial overgrowth, an altered innate immune response, and impaired intestinal transit. We
investigated whether lubiprostone, which can activate the CLC2 Cl
- channel, would improve the intestinal
phenotype in CF mice.
Methods: Cftr
tm1UNC (CF) and wildtype (WT) littermate mice on the C57BL/6J background were used. Lubiprostone
(10 μg/kg-day) was administered by gavage for two weeks. Mucus accumulation was estimated from crypt lumen
widths in periodic acid-Schiff base, Alcian blue stained sections. Luminal bacterial load was measured by qPCR for
the bacterial 16S gene. Gastric emptying and small intestinal transit in fasted mice were assessed using gavaged
rhodamine dextran. Gene expression was evaluated by Affymetrix Mouse430 2.0 microarray and qRT-PCR.
Results: Crypt width in control CF mice was 700% that of WT mice (P < 0.001). Lubiprostone did not affect WT
crypt width but, unexpectedly, increased CF crypt width 22% (P = 0.001). Lubiprostone increased bacterial load in
WT mice to 490% of WT control levels (P = 0.008). Conversely, lubiprostone decreased bacterial overgrowth in CF
mice by 60% (P = 0.005). Lubiprostone increased gastric emptying at 20 min postgavage in both WT (P < 0.001)
and CF mice (P < 0.001). Lubiprostone enhanced small intestinal transit in WT mice (P = 0.024) but not in CF mice
(P = 0.377). Among other innate immune markers, expression of mast cell genes was elevated 4-to 40-fold in the
CF intestine as compared to WT, and lubiprostone treatment of CF mice decreased expression to WT control levels.
Conclusions: These results indicate that lubiprostone has some benefits for the CF intestinal phenotype, especially
on bacterial overgrowth and the innate immune response. The unexpected observation of increased mucus
accumulation in the crypts of lubiprostone-treated CF mice suggests the possibility that lubiprostone increases
mucus secretion.
Background
Cystic fibrosis (CF) is an autosomal recessive disease
caused by mutations in the gene encoding the cystic
fibrosis transmembrane conductance regulator (CFTR),
a cAMP-regulated anion channel. CFTR is crucial for
epithelial Cl
--dependent fluid transport and bicarbonate
ion-dependent pH regulation of luminal spaces. As a
consequence, in CF, epithelial surfaces are poorly
hydrated and abnormally acidic. These conditions con-
tribute to impaired turnover of the protective mucus
layer on epithelial surfaces. Accumulation of mucus is
permissive for abnormal microbial colonization and
growth which leads to inflammation and tissue damage.
Currently used treatments for CF are largely aimed at
symptomatic relief. Various novel approaches that cor-
rect mutant CFTR function [1], or activate alternate
electrolyte secretory mechanisms are under investigation
[2]. These new approaches are attractive therapeutic
options as they would correct the underlying defect and
hence are expected to also improve the subsequent
complications that occur due to loss of CFTR function.
The CF mouse gastrointestinal tract provides a useful
model to test potential therapies because of the wide-
ranging and dramatic changes that occur compared to
control WT mice. These changes also occur in human
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accumulation of luminal mucus [5,6], microbial coloni-
zation of the mucus resulting in bacterial overgrowth
[4,5,7], altered innate immune response [8,9], and
impaired gastrointestinal motility [10-12]. We have pro-
posed that the initiating event in the intestinal patho-
genesis in CF is slowed turnover of luminal mucus due
to the decreased fluid secretion and abnormally acidic
pH of the luminal fluid that occur as a result of lack of
normal CFTR function. The static mucus in the CF
mouse small intestine becomes overgrown with colonic-
type bacteria which upregulate some innate defenses,
including a dramatic influx of mast cells [9] and altered
prostaglandin metabolism [13].
We have shown previously that administration of an
oral osmotic laxative largely corrects the intestinal
phenotype in CF mice [10]. This demonstrates the
benefit of improving the hydration state of the intest-
inal lumen on the CF phenotype, and supports the
rationale to explore therapies that activate fluid secre-
tion mechanisms.
In this work we used the synthetic bioactive bicyclic
fatty acid lubiprostone. Lubiprostone was approved by
the FDA for treatment of chronic constipation in 2006.
It is believed to have beneficial effects via enhanced
fluid secretion and perhaps by increasing gut motility
[14], although the latter effect is not firmly established
as yet [15,16]. Lubiprostone increases fluid secretion
from CF respiratory epithelial cells [2] and maybe also
from airway submucosal glands [17]. Also, a recent case
study reported improvement of constipation in adult CF
patients [18]. The mechanism of action of lubiprostone
is controversial, as discussed in a recent review [19].
Lubiprostone has been shown to activate the CLC2 (also
known as CLCN2) Cl
- channel and stimulate apical fluid
secretion that is independent of CFTR function
[2,20-22]. However, lubiprostone can also activate the
CFTR Cl
- channel [20,23,24]. There are also data sug-
gesting that lubiprostone-induced chloride secretion is
completely CFTR-dependent [23]. Despite these contro-
versial issues, the encouraging results using lubiprostone
in CF patients [18] and with CF cells and tissues [2,17],
made it reasonable to test the hypothesis that lubipros-
tone would ameliorate the intestinal phenotype in the
Cftr knockout mouse.
Methods
Animals
Mice with a targeted null mutation in the Cftr gene
(Cftr
tm1UNC) were originally obtained from Jackson Labs.
They have been bred onto the C57BL/6J background
until congenic [9]. Cftr heterozygous mice were bred to
obtain Cftr null (CF) and wild type (WT) littermates. All
mice, including WT and CF control and experimental
mice, were fed a liquid diet (Peptamen, Nestle Nutrition,
Florham Park, NJ, USA) which prevents lethal intestinal
obstruction in CF mice. Administration of lubiprostone
(Takeda Pharmaceutical North America, Deefield, IL,
U S A )w a sb yao n c ed a i l yg a v a g eo f1 0 0μl Peptamen
containing a stable emulsion of lubiprostone. Prelimin-
ary experiments showed that a dose of 10 μg/kg-day
was maximally effective (this dose maximally affected
gastric emptying, data not shown). Mice were treated
with lubiprostone for a period of 2 weeks before sacri-
fice. The effect of lubiprostone on body weight gain was
assessed. To increase the statistical power of these com-
parisons, weights of CF mice were calculated as percent
of WT mice of the same age, gender, and treatment
group as previously described [10]. All animal work was
approved by the Institutional Animal Use and Care
Committe, of the Univeristy of Kansas Medical Center.
Morphometry
The width of crypts stained with periodic acid-Shiff
base, Alcian blue, pH 2.5 (PAS/AB) was used to esti-
mate the amount of mucus accumulation as previously
d e s c r i b e d[ 1 0 ] .B r i e f l y ,m i c e were fasted overnight with
free access to water, and after sacrifice the small intes-
tines were carefully resected keeping the luminal con-
tents in place. The tissues were fixed overnight in
Carnoy’s solution to preserve mucus. The middle por-
tion of the small intestine was used [10], and tissues
were paraffin embedded and processed for PAS/AB
staining (performed by Mass Histology, Worcester,
MA). From each animal (at least 5 per group), 4 sec-
tions were imaged and crypt regions were recorded on
a digital camera using a 20X objective on a Nikon
microscope. Between 200-300 crypts per sample were
imaged and measured using NIH Image J software as
described [10]. For each group, the averages of the
mean crypt width of each animal were determined and
these averages (n ≥ 5 per group) used for statistical
analysis.
Estimation of bacterial load
The copy number of the bacterial 16S rRNA gene per
intestine was used as an estimate of bacterial load in
the small intestine as previously described [10]. Briefly,
mice were fasted overnight with free access to water.
The entire small intestine was resected and flushed
with PBS containing the mucolytic reducing agent
dithiothreitol (10 mM). The flushed material was cen-
trifuged and the pellet was processed to extract bacter-
ial DNA, using the QIAamp DNA Stool Mini Kit
(Qiagen, Valencia, CA, USA) with minor modifications
as previously reported [4]. The DNA was used to
amplify the bacterial 16S rRNA gene with universal
primers by quantitative PCR.
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transit
Gastric emptying and small intestinal transit were mea-
sured as previously described [10]. Briefly, mice were
fasted overnight and in the morning they were gavaged
with the nondigestible, nonabsorbable tracer rhodamine
dextran (70 kDa, Sigma). Twenty min later, mice were
sacrificed and the distribution of fluorescence in the sto-
mach and 10 equal segments of the small intestine was
measured. There was no tracer in the cecum or colon in
any of the mice at 20 min postgavage. Gastric emptying
was calculated from the amount of tracer remaining in
the stomach relative to the total fluorescence. Small
intestinal transit was measured from the distribution of
fluorescence in the small intestine (excluding that left in
the stomach). For statistical analysis of small intestinal
transit, the data were converted to geometric center of
the fluorescence (GCF) = Σ (fraction per segment × seg-
ment number).
Analysis of gene expression
Equal amounts of total RNA from individual samples
were pooled from mice in each group and were used
to interrogate the Affymetrix Mouse 430 2.0 Gene-
Chip (Affymetrix, Santa Clara, CA, USA). We used 8
WT control, 7 WT + lubiprostone, 10 CF control, and
8 CF + lubiprostone RNA samples to create the pools
for analysis (sample size n = 1 per group). Microarray
data were analyzed using the GeneChip Operating
System (GCOS) software (Affymetrix), using the WT
control data as the baseline. The full microarray data-
set is deposited in NCBI’s Gene Expression Omnibus
[25] and is accessible through GEO Series accession
number GSE18327 http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE18327. Changes in expression
of genes of interest from the microarrays were verified
using quantitative RT-PCR. Briefly, total RNA was
prepared from the entire small intestine by the Trizol
method as previously described [4]. Real time qRT-
PCR was performed with an iCycler instrument (Bio-
Rad, Hercules, CA, USA) using a one-step RT-PCR kit
(Qiagen). The mRNA for ribosomal protein L26
(Rpl26) was used as a housekeeping gene for normali-
zation. Expression levels were calculated using the
ΔΔCt method after correcting for differences in PCR
efficiencies [26], and were expressed relative to WT
control levels.
Statistics
Data are presented as means ± SE. Significance was
determined with Systat 11 software (San Jose, CA) by
ANOVA, or Mann Whitney U test when data were not
normally distributed. P-values < 0.05 were considered as
significant.
Results
Body weight gain
One of the most obvious effects of CF is poor body
weight gain in early life. Although CF mice are pancrea-
tic sufficient, in contrast to most CF patients, CF mice
are about 70% the mass of WT mice from before wean-
ing into early adulthood [27]. Lubiprostone was admi-
nistered for 2 weeks and body weight gain was
measured in WT and CF mice. Lubiprostone did not
affect weight gain in WT mice as compared to control
WT. Similarly, lubiprostone did not improve body
weight gain in CF mice over the two week treatment
period (Fig. 1).
Mucus accumulation
A major phenotype in the CF intestine is accumulation
of mucus (Fig. 2B), believed to be due to the dehydrated
acidic luminal environment that occurs in the absence
of normal CFTR function. Morphologically, there was
not a noticeable effect of lubiprostone treatment on
either WT (Fig. 2C) or CF (Fig. 2D) intestinal tissue. To
be more rigorous, the effect of lubiprostone treatment
on mucus accumulation was estimated from the width
of small intestinal crypts, as previously described [5].
There was no effect of lubiprostone on crypt width in
WT mice (Fig. 3A,C). Crypt width in control CF mice
was ~700% that of control WT mice (Fig. 3). It was
expected that lubiprostone would improve hydration
and reduce mucus accumulation in the CF mouse.
Unexpectedly, in lubiprostone treated CF mice the crypt
the width was 22% greater than control CF mice (Fig.
3B,C).
Figure 1 Effect of lubiprostone treatment on body weight gain
in CF male and female mice. Body weights of lubiprostone
treated CF mice are expressed as percent of WT mice of the same
age and gender. Data are means ± SEM from lubiprostone treated
mice (6 WT males, 6 WT females, 10 CF males, 10 CF females). There
were no significant differences.
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We had hypothesized that lubiprostone would reduce
mucus accumulation in the CF intestine. Since bacteria
colonize and grow in the accumulated mucus of the CF
i n t e s t i n e[ 4 ] ,w ee x p e c t e dt h a tl u b i p r o s t o n ew o u l d
reduce the bacterial load in the CF intestine. Therefore,
the effect of lubiprostone on bacterial load was exam-
ined. In WT mice treatment with lubiprostone increased
bacterial load to almost 500% that of control WT mice
(Fig. 4). As previously reported [4] the bacterial load in
control CF mice was more than 10,000% that of control
WT mice (Fig. 4). In lubiprostone treated CF mice there
was a significant reduction in bacterial load by 60% as
compared to control CF mice (Fig. 4).
Gastrointestinal transit
The CF phenotype also includes effects on gastrointest-
inal motility [28]. Gastric emptying in CF mice is not
significantly different from that in WT at 20 min post-
gavage [28], but it is less at 90 min postgavage [29]. In
the current work, we confirmed that at 20 min postga-
vage there is not a significant difference in gastric emp-
tying comparing control CF to WT (Fig. 5). In
lubiprostone treated mice, gastric emptying was signifi-
cantly greater in both WT and CF mice as compared to
the respective control animals (Fig. 5).
CF mice have strongly impaired small intestinal transit
as compared to WT [28] which was confirmed here
(Fig. 6A, B). Small intestinal transit was slightly greater
Figure 2 Morphology of WT and CF small intestine without and with lubiprostone treatment. Mice were treated with lubiprostone (10
μg/kg-day) for two weeks, as indicated. After an overnight fast, the small intestine was fixed in Carnoy’s solution and processed for PAS/AB
staining. The CF intestine has much greater mucus in the crypts as well as along the villus surfaces, as compared to WT tissue. There was not an
obvious effect of lubiprostone on mucus in either WT or CF mice as compared to controls.
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mice (Fig. 6A, B). The transit data were statistically ana-
lyzed by transforming them to the geometric center of
fluorescence (GCF) values. The GCF in lubiprostone
treated WT mice was significantly greater as compared
to control WT (Fig. 6C). There was not a significant dif-
Figure 3 Effect of lubiprostone treatment on mucus
accumulation in the small intestine as measured by crypt
lumen width in WT and CF mice. Crypt widths of Carnoy’s fixed,
PAS/AB stained sections were used as an estimate of mucus
accumulation. A. Frequency distribution of crypt widths in WT
control and lubiprostone (+Lubi) treated mice. B. Frequency
distribution of crypt widths in CF control and lubiprostone (+Lubi)
treated mice. C. Summary of crypt widths in control (Con) and
lubiprostone (Lubi) treated WT and CF mice. Horizontal bars
represent the group means. (8 WT control, 5 WT + lubiprostone, 6
CF control, 5 CF + lubiprostone; *: P < 0.00001 CF control vs. WT
control; + P = 0.00004 CF +Lubi vs. CF control)
Figure 4 Effect of lubiprostone on bacterial load in the small
intestinal lumen of WT and CF mice. After an overnight fast, the
contents of the small intestine were flushed with a mucolytic agent,
and the flushed material was processed to measure copies of the
bacterial 16 S rRNA gene by quantitative PCR (see Materials and
Methods). Horizontal bars represent the group means. [5 WT control
(Con), 12 WT + lubiprostone (Lubi), 6 CF control, 18 CF +
lubiprostone; *: P = 0.008 CF control vs. WT control; +: P < 0.010
+Lubi vs. control of same genotype]
Figure 5 Effect of lubiprostone on gastric emptying in WT and
CF mice. Mice were fasted overnight and in the morning gavaged
with the nondigestible, nonabsorbable tracer rhodamine dextran (70
kDa). Twenty minutes later the mice were sacrificed and the
amount of tracer remaining in the stomach relative to the gavaged
amount was measured. Horizontal bars represent the group means.
[30 WT control (Con), 12 WT + lubiprostone (Lubi), 15 CF control, 20
CF +Lubi; +: P < 0.001 +Lubi vs. control of same genotype]
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ted CF to control CF mice.
Microarray and qRT-PCR analysis of gene expression
There are numerous changes in gene expression in the
CF mouse small intestine as revealed by analysis of glo-
bal expression levels using the Affymetrix U74Av2 Gen-
eChip [9]. Therefore, it was of interest to see how
lubiprostone treatment affected gene expression in WT
and CF mice. Because we had previously performed this
type of analysis in control WT and CF mice, in the cur-
rent work we used total RNA samples pooled by group
to investigate global gene expression effects of lubipros-
tone, using the newer Mouse 430 2.0 GeneChip (see
Methods). The major changes in gene expression in the
CF intestine reported previously were replicated in the
new analysis (both complete datasets are deposited at
Genome Expression Omnibus website, GEO Series
accession numbers GSE765 and GSE18327, respectively,
at http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE765 and http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE18327. We used an arbitrary cut-
off of 3-fold to select genes whose expression was chan-
ged by lubiprostone treatment. We chose several of the
genes indicated by the arrays for verification by quanti-
tative RT-PCR.
There were 18 genes on the arrays whose expression
was ≥ 3-fold greater in the CF control sample as com-
pared to WT control, that were also downregulated ≥ 3-
fold by lubiprostone treatment of CF mice (Table 1).
Ten of these genes are associated with immunity, eight
of which are involved with innate immunity including
five markers of mast cells. Another four genes are asso-
ciated with growth or differentiation, three of which are
members of the gasdermin gene family. The remaining
three genes are involved in various functions that do
not fall into obvious functional groups.
By qRT-PCR we examined 5 of the genes that were
indicated on the arrays as being upregulated in CF com-
pared to WT, and downregulated in CF treated with
lubiprostone. As previously reported [9], resistin-like b
(Retnlb) was very highly increased in the CF intestine
(Fig. 7A). Whereas the arrays indicated a 3-fold decrease
in Retnlb expression in the lubiprostone treated CF
intestine, there was not a significant decrease as mea-
sured by qRT-PCR (Fig. 7A). The arrays showed a large
upregulation of chitinase 3-like 4 (Chi3l4, also known as
Ym2) (Table 1). By qRT-PCR there were similar changes
in Chi3l4 expression but because of the high variability
in the CF control group, the differences were not statis-
tically significant (Fig. 7B). We were able to confirm by
qRT-PCR that phospholipase A2 group 4c (Pla2g4c),
gasdermin c2 (Gsdmc2 also known as MLZE, mela-
noma-derived leucine zipper-containing extranuclear
Figure 6 Effect of lubiprostone on small intestinal transit in WT
and CF mice. Mice were fasted overnight and in the morning
gavaged with the nondigestible, nonabsorbable tracer rhodamine
dextran (70 kDa). Twenty minutes later the mice were sacrificed and
the distribution of tracer along the small intestine was measured. A.
Distribution of rhodamine along the intestine of WT control and
lubiprostone (+Lubi) treated mice. B. Distribution of rhodamine
along the intestine of CF mice control and lubiprostone treated
mice. C. Geometric center of fluorescence in control (Con) WT and
CF mice and lubiprostone (Lubi) treated WT and CF mice. Horizontal
bars represent the group means. [30 WT control, 12 WT +
lubiprostone, 15 CF control, 20 CF + lubiprostone; *: P < 0.00001 CF
control vs. WT control; + P = 0.03 WT +Lubi vs. WT control]
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all upregulated in CF controls and downregulated to
WT control levels in lubiprostone treated CF mice (Fig.
7C-E). In addition to Mcpt2, several other mast cell
markers on the arrays were strongly upregulated in CF
controls and decreased 3-20 fold in lubiprostone treated
CF mice (Table 1).
There were 11 genes whose expression was ≥ 3-fold
lesser in the CF control sample as compared to WT
controls, and whose expression was upregulated ≥ 3-fold
by lubiprostone treatment of CF mice (Table 2). Four of
these genes are involved in lipid metabolism, including
production of eicosanoids. Another three genes are
involved in glucose metabolism (Table 2). And, another
three are involved in solute transport (Table 2). By qRT-
PCR we verified these changes for Slc5a12 (sodium
monocarboxylate transporter) and Cyp4a10 (cytochrome
P450 4a10, which converts arachidonic acid to 20-
HETE) (Fig. 7F and 7G, respectively).
On the arrays, there were 4 genes upregulated ≥3-fold
in lubiprostone treated WT mice as compared to WT
control, and 40 genes upregulated ≥3-fold in lubipros-
tone treated CF mice as compared to CF control (see
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE18327). None of these genes was upregulated in
common in both WT and CF lubiprostone treated mice.
Also, there were 24 genes whose expression was down-
regulated ≥ 3-fold in lubiprostone treated WT mice as
compared to WT control, and 32 genes downregulated
≥ 3-fold in lubiprostone treated CF mice as compared
to CF control (see http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE18327). None of these genes was
d o w n r e g u l a t e di nc o m m o ni nb o t hW Ta n dC Fl u b i -
prostone treated mice.
Since mucus accumulation in CF crypts appeared to
be increased by lubiprostone treatment, we also mea-
sured expression levels of the two major mucin genes
expressed in the small intestine, Muc2 and Muc3. There
were no significant differences in Muc2 expression levels
comparing any of the four groups of mice (Fig. 7H).
Expression of Muc3 was modestly but significantly
increased in lubiprostone treated WT mice, but there
was not a significant difference in lubiprostone treated
CF mice (Fig. 7I).
Discussion
Cystic fibrosis is caused by loss of function of the cAMP
regulated anion channel CFTR. Therefore, we hypothe-
sized that lubiprostone, which has been reported to acti-
vate the non-CFTR Cl
- channel CLC2, would improve
Table 1 Genes upregulated in the control CF intestine as compared to control WT, and downregulated by
lubiprostone treatment of CF mice.
CF WT+L CF+L Symbol Name Function/Process
1176 1.52 365 Retnlb resistin like beta Innate immunity
112 3.11 4.5 Chi3l4 chitinase 3-like 4 Innate immunity
51 0.52 8.7 Pla2g4c phospholipase A2, group IVC (cytosolic, calcium- independent) Inflammation, eicosanoid metabolism
42 0.76 3.4 Mcpt1 mast cell protease 1 Innate immunity, mast cell
23 1.32 2.8 Spna1 spectrin alpha 1 Erythrocyte cytoskeleton
18 0.23 1.3 Gsdmc2 gasdermin C2 Growth, differentiation, apoptosis
16 0.76 1.4 Mcpt2 mast cell protease 2 Innate immunity, mast cell marker
14 1.15 2.1 Mcpt9 mast cell protease 9 Innate immunity, mast cell
12 1.32 3.7 B3galt5 UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 5 Sialyl Lewis-a synthesis
11 4.92 2.1 Ube2l6 ubiquitin-conjugating enzyme E2L 6 Innate immunity, ISG15- ubiquitination
8.6 1.00 1.2 Capn13 calpain 13 Growth, differentiation, apoptosis
8.0 0.23 1.4 Gsdmc4 gasdermin C4 Growth, differentiation, apoptosis
7.0 0.27 1.3 Gsdmc gasdermin C Growth, differentiation, apoptosis
4.9 0.44 1.4 Cpa3 carboxypeptidase A3, mast cell Innate immunity, mast cell marker
4.0 0.76 0.2 Fcer1a Fc receptor, IgE, high affinity I, alpha polypeptide Innate immunity, mast cell marker
3.7 1.15 1.4 Egln3 EGL nine homolog 3 (C. elegans) Prolyl hydroxylation of HIF
3.5 1.62 1 (none) single chain antibody ScFv Immunoglobulin heavy chain, immunity
3.2 0.56 0.5 Scd2 stearoyl-Coenzyme A desaturase 2 Unsaturated fatty acid synthesis
Genes whose expression level in the CF control intestine were ≥ 3-fold greater than WT control and were downregulated ≥ 3-fold by lubiprostone in CF mice.
Expression values are data from the GCOS analysis relative to WT control levels. When there were multiple probe sets for a particular gene the values were
averaged. Gene names are according to the Mouse Genome Informatics website http://www.informatics.jax.org/. +L = lubiprostone treated. Equal amounts of
total RNA were pooled from 7-10 mice in each group and were used to interrogate the Affymetrix Mouse 430 2.0 GeneChip (n = 1 per group). The full
microarray dataset is deposited in NCBI’s Gene Expression Omnibus and is accessible through GEO Series accession number GSE18327 http://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE18327.
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Page 7 of 12Figure 7 Verification of microarray results for selected genes by qRT-PCR. (A) Retnlb, resistin-like b, also known as Fizz2; (B) Chi3l4, chitinase
3-like 4, also known as Ym2; (C) Pla2g4c, phospholipase A2, group 4c; (D) Gsdmc2, gasdermin c2; (E) Mcpt2, mast cell protease 2; (F) Slc5a12,
sodium-monocarboxylate transporter; (G) Cyp4a10, cytochrome P450 4a10; (H) HemT1, hematopoietic cell transcript 1; (I) Muc2, mucin 2; (J) Muc3,
mucin 3. All data are normalized to expression of ribosomal protein 26 (Rpl26) and are relative to WT control expression levels. Data are means ±
SEM; *: P< 0.05 comparing CF control to WT control; +: P < 0.05 +Lubi compared to control of same genotype. (n = 8 WT controls, 6 WT
lubiprostone treated, 8 CF controls, 6 lubiprostone treated CF samples)
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Administration of lubiprostone improved aspects of the
CF phenotype, notably small intestinal bacterial over-
growth and the innate immune response, but did not
affect others, including small intestinal transit and body
weight gain.
Effect on mucus accumulation
It was hypothesized that if lubiprostone improved the
hydration of mucus this would allow more normal
mucus turnover in the CF intestine. We estimated
mucus accumulation morphometrically by the width of
PAS/AB stained crypts, and unexpectedly, the crypt
width was significantly increased in lubiprostone treated
CF mice as compared to control CF mice. One possible
explanation is that fluid transport stimulated by lubi-
prostone increases the hydration of released mucins (the
h i g h l yg l y c o s y l a t e dp r o t e i n st h a tf o r mm u c u s )c a u s i n g
the mucus to swell more, and thus widening the crypt
lumen. If this explanation is correct, it would suggest
that the amount of fluid secretion induced by lubipros-
tone was not sufficient to flush out the cul-de-sac that is
the intestinal crypt, which in CF has excessive mucin
secretion.
Another possibility is that lubiprostone-induced fluid
secretion enhances mucin release from intestinal goblet
cells. It has been demonstrated that mucin release from
a goblet cell-like cell line is accompanied by Cl
- depen-
dent fluid secretion, suggesting a functional coupling
between these two processes [30]. Also, it was shown
that CFTR function supports efficient release of soluble
mucin from the mouse small intestine [31] and CFTR
has been implicated in mucin release from a tracheal
gland cell line [32]. Lubiprostone has been shown to sti-
mulate duodenal bicarbonate (HCO3
-)s e c r e t i o n[ 2 0 ]
and HCO3
- ion supports efficient intestinal mucin
release [31].
An alternate possibility is that lubiprostone acts as a
secretagogue that stimulates an intracellular messenger
pathway leading to mucin exocytosis from goblet cells.
It is known that PGE2 is a potent mucin secretagogue
[31]. There is also evidence that lubiprostone can acti-
vate PGE2 receptors [23,33], but this has not been uni-
versally confirmed [24,34]. If lubiprostone stimulates
mucin release, the fact that crypt width was not
increased in lubiprostone-treated WT mice would sug-
gest that there is sufficient fluid secretion in WT mice
to prevent mucus accumulation in the crypt lumen as
occurs in CF. Thus, lubiprostone may enhance mucin
release through its effects on fluid secretion, or more
directly through activation of mucin granule exocytosis
via prostaglandin receptor activation.
Effect on bacterial load
It was predicted that lubiprostone would reduce bacter-
ial overgrowth of the CF small intestine, and there was
a significant 60% reduction in bacterial load in lubipros-
tone treated CF mice. An obvious mechanism is that
enhanced fluid secretion improves solubility and turn-
over of luminal mucus that bacteria colonize. It was
unexpected that lubiprostone treatment would affect
bacterial load in WT mice, but we observed increased
bacterial load of ~500%. This result does not appear
compatible with an effect of lubiprostone on fluid secre-
tion; increased fluid secretion is not expected to increase
the ability of bacteria to colonize and grow in the WT
Table 2 Genes downregulated in the control CF intestine as compared to control WT, and upregulated by
lubiprostone treatment of CF mice.
CF WT+L CF+L Symbol Name Function/Process
0.01 0.4 0.11 Slc5a12 solute carrier family 5 (sodium/glucose cotransporter), member 12 Na-monocarboxylate transporter
0.05 0.4 0.33 Cyp4a10 cytochrome P450, family 4, subfamily a, polypeptide 10 20-HETE synthesis
0.08 0.9 0.46 Pck1 phosphoenolpyruvate carboxykinase 1, cytosolic Glucose metabolism
0.12 0.6 1.1 Pdk4 pyruvate dehydrogenase kinase, isoenzyme 4 Glucose metabolism
0.15 1.3 0.53 Fbp1 fructose bisphosphatase 1 Glucose metabolism
0.21 1.2 2.14 Hmgcs2 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 Ketogenesis
0.21 1.1 1.74 Acot2 acyl-CoA thioesterase 2 Fatty acid metabolism
0.25 1.1 0.93 Slc13a2 solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 2 Na-dicarboxylate transporter
0.25 1.1 1.33 Sgk1 serum/glucocorticoid regulated kinase 1 Regulation of electrolyte transport
0.33 1.6 1.32 Akr1b7 aldo-keto reductase family 1, member B7 PGF2a synthesis
0.33 1.1 2.15 Angptl4 angiopoietin-like 4 Lipid metabolism
Genes whose expression level in the CF control intestine were ≥ 3-fold less than WT control and were upregulated ≥ 3-fold by lubiprostone in CF mice.
Expression values are data from the GCOS analysis relative to WT control levels. Gene names are according to the Mouse Genome Informatics website http://
www.informatics.jax.org/. +L = lubiprostone treated. Equal amounts of total RNA were pooled from 7-10 mice in each group and were used to interrogate the
Affymetrix Mouse 430 2.0 GeneChip (n = 1 per group). The full microarray dataset is deposited in NCBI’s Gene Expression Omnibus and is accessible through
GEO Series accession number GSE18327 http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE18327.
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lates mucin secretion from goblet cells, it could be that
more mucus in the intestinal lumen is available for bac-
terial colonization and growth in WT mice. One would
then have to propose that greater mucus release in the
CF intestine, in combination with enhanced anion and
fluid secretion, is sufficient to increase mucus clearance
and thereby reduce the bacterial load in lubiprostone
treated CF mice. Because of the complex behavior of
mucus, it is difficult to know if this explanation can
account for the opposite effects of lubiprostone on bac-
terial load in the WT vs. CF small intestine.
Effects on the CF intestine innate immune response
Treatment of CF mice with lubiprostone decreased
expression of several innate immunity genes. Included
in these are markers of mast cells which are dramatically
increased in the control CF intestine and whose expres-
sion was reduced to WT levels in lubiprostone treated
CF mice. This indicates that the dramatic influx of mast
cells into the CF mouse small intestine [9] is reversed
by lubiprostone treatment. Another gene involved in
inflammation, Pla2g4c, calcium-independent phospholi-
pase A2, group 4c (also known as PLA2g)w a ss t r o n g l y
upregulated in the CF intestine and downregulated to
WT control levels by lubiprostone treatment. This
enzyme was shown to be induced in jejunal epithelium
by nematode infection of the small intestine [35]. Our
results indicate that Pla2g4c expression is also increased
by bacterial overgrowth which occurs in the CF intestine
and lubiprostone reverses its upregulation.
It remains to be determined how lubiprostone
decreased the innate immune response in CF mice. One
possibility is that, since the bacterial load was signifi-
cantly decreased by lubiprostone treatment, this may
have reduced the immune response. However, in a pre-
vious study we showed that oral administration of the
mucolytic N-acetylcysteine reduced bacterial load to the
same extent as in lubiprostone treated CF mice, but
there was no improvement in the innate immune
response gene expression levels with N-acetylcysteine
[10]. Another possibility is that lubiprostone activates a
prostaglandin receptor and has anti-inflammatory or
some other protective effect. Prostaglandins, to which
lubiprostone is structurally related, are gastroprotective
in large part due to their stimulation of bicarbonate and
mucus secretion. Perhaps lubiprostone acts in a similar
fashion to improve the innate response of the CF intes-
tine. Lubiprostone has been reported to stimulate bicar-
bonate secretion which was suggested to be through
activation of the EP4 PGE2 receptor [20] and activation
of Cl- secretion was blocked by an EP4 receptor antago-
nist [23]. However, other work has shown that lubipros-
tone does not have appreciable affinity for the EP4
receptor [24,33], so the mechanism by which lubipros-
tone stimulates bicarbonate secretion remains uncertain
[19].
A family of genes whose expression was upregulated
in the CF intestine and downregulated by lubiprostone
treatment are the gasdermins. The gasdermins have
been shown in cell culture to be anti-apoptotic and are
thought to be involved in regulation of growth and dif-
ferentiation [36]. It is interesting to note that the epithe-
lium of the CF mouse small intestine is hypertrophied
and both crypts and villi are larger than in WT mice
[10,37], which is consistent with the role of gasdermins.
However, even though expression of gasdermins was
downregulated in lubiprostone-treated CF mice, the
epithelium was still hypertrophied (Fig. 2D). It may be
that the two week treatment period was not sufficient to
reverse the hypertrophic state of the epithelium, or that
other factors are of greater importance.
Effects on GI motility
We observed two effects of lubiprostone on GI motility.
First, lubiprostone increased gastric emptying in both
WT and CF mice. CLC2 is present in the stomach and
was suggested to be the Cl
- channel required for gastric
acid secretion [38]. Lubiprostone-induced fluid secretion
in the stomach may increase the rate of emptying of the
water soluble tracer used (rhodamine-dextran), which
would explain the stimulatory effects of lubiprostone on
gastric emptying we observed. In contrast, in a human
study, lubiprostone was shown to increase fasting gastric
volume and inhibit emptying of a solid nutrient test
meal [14]. A likely explanation for these different results
is that we used non-nutritive tracer and vehicle in our
work, and this is expected to measure activity of the
interdigestive migrating motor complex; on the other
hand, the human study used a solid nutrient test meal,
which in itself will affect motility programs, and this
model will measure postprandial motility.
The mechanism of action of lubiprostone is the sub-
ject of debate [19]. Early work using cell transfection
studies showed that Cl
- transport stimulated by lubi-
prostone was mediated by the CLC2 gene product [22].
However, at drug concentrations >100 nM, the CFTR
Cl
- channel is also activated [39]. A recent study using
guinea pig ileum concluded that Cl
- secretory effects of
lubiprostone were not mediated by CFTR, but were con-
sistent with activation of CLC2 [24]. However, in
another recent study using mice, various cell lines, and
human control and CF patient intestinal tissues, it was
concluded that the action of lubiprostone required
CFTR [23]. Whether these disparate results are due to
species or methodological differences is unclear at this
point. Since we used Cftr null mice, the effects of lubi-
prostone in our experiments cannot be through the
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- secretory response to lubipros-
tone in the mouse small intestine is CFTR-dependent as
recently reported [23], our results would indicate that
lubiprostone’s effects in Cftr null mice are through
another pathway, such as a prostaglandin receptor.
Since PGE2 can stimulate murine duodenal HCO3
- ion
secretion (via the SLC26A6 transporter but not through
CFTR [40]), it may be that lubiprostone enhances
HCO3
- secretion, which is expected to improve mucus
solubility [31]. Despite the uncertainties regarding lubi-
prostone’s mechanism of action, there were significant
changes in lubiprostone treated CF mice which demon-
strate that lubiprostone has CFTR independent effects
in the mouse small intestine that are beneficial to the
CF phenotype.
Conclusions
Treatment of CF mice with lubiprostone ameliorates
the CF intestinal phenotype. There was a significant
decrease in bacterial overgrowth and normalized
expression levels of several innate response genes,
especially for mast cell markers. Because there are sig-
nificant differences between mice and humans, it will
be important to further test the potential intestinal
benefits of lubiprostone in CF patients. It is an open
question whether the beneficial effects of lubiprostone
in the CF mouse are due to stimulation of Cl
- and
fluid secretion. There is also the possibility that lubi-
prostone activates prostaglandin receptors, perhaps sti-
mulating mucin and HCO3
- secretion, and having
additional anti-inflammatory effects mediated through
such receptors. If lubiprostone enhances mucin and
HCO3
- release this drug also may be beneficial for var-
ious GI conditions where bolstering production of the
protective mucus layer is desirable, such as gastric
ulcer and enteric infection.
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